Clinical Trial Update: A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting ongoing recruitment for a combination therapy (agenT-797 with Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel) in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Balstilimab (balstilimab)
• Botensilimab (botensilimab)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)
• agenT-797 (agenT-797)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma | Phase 2 | Status: RECRUITING